Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”

Published byIrene Meghan Montgomery Modified over 8 years ago

Similar presentations

Presentation on theme: "Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”"— Presentation transcript:

1 Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI” group. The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files A Hazard Ratios 95% CI

2 Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI” group. The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files B Hazard Ratios 95% CI

3 Figure 7: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for women in various BMI groups compared to patients in the “normal BMI” group. The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files A Hazard Ratios 95% CI

4 Figure 7: Risks of outcomes in the primary (C) and secondary (B) prevention cohorts for women in various BMI groups compared to patients in the “normal BMI” group. The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files B Hazard Ratios 95% CI

5 Figure 8: Risks of outcomes in the secondary prevention cohort for patients in five quintiles (Q) of waist circumference (WC) compared to patients in the 2 nd quintile of WC. The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. Supplementary data files ‘’ Hazard Ratios 95% CI ‘’

6 Figure 9: Risks of outcomes in the secondary prevention cohort for patients with optimal therapy (A) and suboptimal therapy (B) in five quintiles (Q) of waist circumference (WC) compared to patients in the reference group (quintile 2). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. A Supplementary data files Hazard Ratios 95% CI ‘’

7 Figure 9: Risks of outcomes in the secondary prevention cohort for patients with optimal therapy (A) and suboptimal therapy (B) in five quintiles (Q) of waist circumference (WC) compared to patients in the reference group (quintile 2). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. B Supplementary data files ‘’ Hazard Ratios 95% CI

8 Figure 10: Risks of outcomes in the secondary prevention cohort for men with optimal therapy (A) and suboptimal therapy (B) in various BMI groups compared to patients in the reference group (18 kg/m²<BMI<25 kg/m²). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files A Hazard Ratios 95% CI

9 Figure 10: Risks of outcomes in the secondary prevention cohort for men with optimal therapy (A) and suboptimal therapy (B) in various BMI groups compared to patients in the reference group (18 kg/m²<BMI<25 kg/m²). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files B Hazard Ratios 95% CI

10 Figure 11: Risks of outcomes in the secondary prevention cohort for women with optimal therapy (A) and suboptimal therapy (B) in various BMI groups compared to patients in the reference group (18 kg/m²<BMI<25 kg/m²). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementary data files A Hazard Ratios 95% CI

11 Figure 11: Risks of outcomes in the secondary prevention cohort for women with optimal therapy (A) and suboptimal therapy (B) in various BMI groups compared to patients in the reference group (18 kg/m²<BMI<25 kg/m²). The hazard ratios and 95% confidence intervals are displayed on a logarithmic scale. ‘’ Supplementarry data files B Favor other BMI Favor BMI 18-25 Hazard Ratios 95% CI

Download ppt "Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”"

Similar presentations

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
© NOO 2011 noo National Obesity Observatory Examining available data for the adult population.

© NOO 2011 noo National Obesity Observatory Examining available data for the adult population.
© NOO 2012 noo National Obesity Observatory Examining available data for the adult population.

© NOO 2012 noo National Obesity Observatory Examining available data for the adult population.
analysis from the SHIFT study

analysis from the SHIFT study
Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.

Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.
Obesity. Statistics 60% of U.S. population are overweight This figure has doubled since 1980. $75 billion spent per year due to obesity 100,000-300,000.

Obesity. Statistics 60% of U.S. population are overweight This figure has doubled since $75 billion spent per year due to obesity 100, ,000.
Pai JK et al. N Engl J Med 2004; 351:2599-2610. Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal100-129 mg/dL Borderline High130-159 mg/dL High160-189 mg/dL.

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.
Normal Distribution.

Normal Distribution.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Shalev V, et al. Arch Intern Med 2009; 169:260-268.

Shalev V, et al. Arch Intern Med 2009; 169:
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.

Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.
Supplementary Appendix. 0 5 10 15 20 25 30 01234567891011 Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

Supplementary Appendix Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)
ACCORD Microvascular Outcomes

ACCORD Microvascular Outcomes
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Ann Intern Med. 2016;164(8): doi: /M Figure Legend:

Ann Intern Med. 2016;164(8): doi: /M Figure Legend:
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.

Similar presentations

Ads by Google